Naslov
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Autori
Infante, Maria Stefania ; Salmanton-García, Jon ; Fernández- Cruz, Ana ; Marchesi, Francesco ; Jakšić, Ozren ; Weinbergerová, Barbora ; Besson, Caroline ; Duarte, Rafael F. ; Itri, Federico ; Valković, Toni ; Szotkovski, Tomáš ; Busca, Alessandro ; Guidetti, Anna ; Glenthøj, Andreas ; Collins, Graham P. ; Bonuomo, Valentina ; Sili, Uluhan ; Seval, Guldane Cengiz ; Machado, Marina ; Cordoba, Raul ; Blennow, Ola ; Abu-Zeinah, Ghaith ; Lamure, Sylvain ; Kulasekararaj, Austin ; Falces-Romero, Iker ; Cattaneo, Chiara ; Van Doesum, Jaap ; Piukovics, Klára ; Omrani, Ali S. ; Magliano, Gabriele ; Ledoux, Marie-Pierre ; de Ramon, Cristina ; Cabirta, Alba ; Verga, Luisa ; López-García, Alberto ; Da Silva, Maria Gomes ; Stojanoski, Zlate ; Meers, Stef ; Lahmer, Tobias ; Martín-Pérez, Sonia ; Dávila-Vals, Julio ; Van Praet, Jens ; Samarkos, Michail ; Bilgin, Yavuz M. ; Karlsson, Linda Katharina ; Batinić, Josip ; Nordlander, Anna ; Schönlein, Martin ; Hoenigl, Martin ; Ráčil, Zdeněk ; Mladenović, Miloš ; Hanakova, Michaela ; Zambrotta, Giovanni Paolo Maria ; De Jonge, Nick ; Adžić-Vukičević, Tatjana ; Nunes-Rodrigues, Raquel ; Prezioso, Lucia ; Navrátil, Milan ; Marchetti, Monia ; Cuccaro, Annarosa ; Calbacho, Maria ; Giordano, Antonio ; Cornely, Oliver A. ; Hernández-Rivas, José-Ángel ; Pagano, Livio

Izvornik
Frontiers in oncology (2234-943X) 12 (2022); 992137, 17

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
SARS-CoV-2 ; chronic lymphocytic leukemia (CLL) ; immune system COVID19 ; infection risk ; lymphoproliferative diseases (LPD) ; non-Hodgkin lymphoma (NHL) ; targeted drugs.

Sažetak
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA